Late Onset Ventilator-Associated Pneumonia Due to Multidrug-Resistant Acinetobacter spp.: Experience with Tigecycline
| Autor: | Francisco Fernández, Daniel Curcio, J. Vergara, C.M. Luna, W. Vazquez |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Adult
Male medicine.medical_specialty Adolescent Minocycline Context (language use) Tigecycline Bronchoalveolar Lavage Drug Resistance Multiple Bacterial Internal medicine Intensive care medicine Humans Pharmacology (medical) Aged Antibacterial agent Aged 80 and over Pharmacology Acinetobacter business.industry Bacterial pneumonia Ventilator-associated pneumonia Pneumonia Ventilator-Associated Middle Aged medicine.disease Anti-Bacterial Agents Surgery Pneumonia Treatment Outcome Infectious Diseases Oncology Colistin Drug Therapy Combination Female business Acinetobacter Infections medicine.drug |
| Zdroj: | Journal of Chemotherapy. 21:58-62 |
| ISSN: | 1973-9478 1120-009X |
| DOI: | 10.1179/joc.2009.21.1.58 |
| Popis: | The aim of the study was to evaluate the clinical success rate of 73 patients with ventilator-associated pneumonia (VAP) caused by multidrug-resistant (MDR)-Acinetobacter spp. treated with tigecycline in seven intensive Care Units in Argentina and to determine which predictor variables were significant in this context. Clinical success in our patients was 69.86% (Ci= 58.65-81.07%) 51/73, without significant differences between patients with VAP due to MDR-Acinetobacter spp. carbapenem-susceptible or carbapenem-resistant and only susceptible to colistin, minocyline and tigecycline (70% 44/73 vs. 69% 29/73 respectively, p=0.9006), and between patients who received48h of prior antibiotics (including those who did not receive any) and those who received48h of prior antibiotics (73.3% 22/30 vs 67.4% 29/43 respectively, p=0.7791). Age67 and using other method than BAL for respiratory sampling were identified as predicting variables for negative clinical outcome. Our results suggest that tigecycline may be an acceptable alternative for therapy in patients with VAP caused by MDR-Acinetobacter spp. Nevertheless, only controlled clinical trials will provide the evidence to support approval for new indications. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|